Clinical Trials
16 trialsNCT00588770 2026-05-26
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06535607 2026-05-26
eVOLVE-02
AstraZeneca
Phase 2 Recruiting
NCT04858269 2026-05-22
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT07601737 2026-05-22
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT03645928 2026-05-15
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
Phase 2 Terminated
NCT05063552 2026-05-13
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT05420948 2026-05-12
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
University of Chicago
Phase 2 Recruiting
NCT04389632 2026-05-11
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT04671667 2026-05-08
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06385080 2026-05-08
OrigAMI-4
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT07276399 2026-05-08
OrigAMI-5
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT04083599 2026-05-06
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT02270814 2026-05-05
CACTUX
Washington University School of Medicine
Phase 2 Active not recruiting
NCT05681039 2026-05-05
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05721755 2026-05-05
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT07441681 2026-05-04
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NRG Oncology
Phase 3 Not yet recruiting